Porsolt, JSW in Research Services Pact

Porsolt and JSW Lifesciences have signed a strategic collaboration agreement to co-market complementary contract research services. Porsolt offers specialized preclinical pharmacology services across many disease areas and physiological systems and processes. JSW brings significant experience in performing a wide range of in vitro, behavioral, histopathology, and immunohistochemistry studies. 

Using standardized and innovative techniques, Porsolt offers services in both efficacy and GLP safety pharmacology. JSW’s extensive capabilities include molecular biological techniques, protein expression systems, monoclonal antibodies and exclusive access to transgenic animal models of neurodegenerative diseases. In addition JSW offers full clinical research services from phase I to phase IV.

“We are excited about working with Porsolt, a leading CRO with a global reputation and presence in numerous different markets. This agreement allows us to combine contract research services, proprietary disease models and technologies, drug discovery capabilities, and provide an expanded portfolio of services for the benefit of the pharma, biotech and research communities,” said Dr. Manfred Windisch, president and chief executive officer of Austria-based JSW.

“JSW’s unique access to exclusive transgenic models of human disease, coupled with their in vitro capabilities, makes them a perfect partner for Porsolt. JSW will become one of our most significant strategic partners, further establishing us as the market leader in fully integrated lead optimization drug discovery services,” commented Dr. Mark Duxon, Porsolt’s chief executive officer.